Corium International (CORI) Stock Price, News & Analysis

Company Overview

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

Key Stats

• Today's Range: $12.68 to $12.68
• 50-Day Range: N/A
• 52-Week Range: $7.17 to $13.93
• Volume: N/A
• Average Volume: 577,723 shs
• Market Capitalization: $459.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CORI Stock Analysis - Frequently Asked Questions

How were Corium International's earnings last quarter?

Corium International, Inc. (NASDAQ:CORI) released its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.04. The biopharmaceutical company had revenue of $7.67 million for the quarter, compared to analyst estimates of $6.72 million. Corium International had a negative trailing twelve-month return on equity of 276.89% and a negative net margin of 155.21%.

What other stocks do shareholders of Corium International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corium International investors own include Bristol-Myers Squibb (BMY), Intelsat (I), Energy Transfer (ET), Iovance Biotherapeutics (IOVA), Exelixis (EXEL), SunCoke Energy Partners (SXCP) and Cypress Semiconductor (CY).

Company Calendar

• Last Earnings: 8/09/2018
• Today: 11/23/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CORI
• CUSIP: N/A
• CIK: 1594337
• Web: www.coriumgroup.com
• Phone: 650-298-8255
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-47,790,000.00
• Net Margins: -155.21%
• Pretax Margin: N/A
• Return on Equity: -276.89%
• Return on Assets: -57.52%

Debt

• Debt-to-Equity Ratio: 2.83
• Current Ratio: 7.61
• Quick Ratio: 7.47

Sales & Book Value

• Annual Sales: $31.86 million
• Price / Sales: 14.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.45 per share
• Price / Book: 28.18

Miscellaneous

• Outstanding Shares: 36,250,000
• Free Float: N/A
• Market Cap: $459.65 million
• Optionable: Optionable
• Beta: 0.87